<DOC>
	<DOCNO>NCT00333736</DOCNO>
	<brief_summary>Hypothesis : Patients use enfuvirtide Biojector improve quality life , great satisfaction , few adverse event compare use standard needle .</brief_summary>
	<brief_title>Study Assess Safety Quality Life Patients Using Biojector Versus Needles Fuzeon Administration</brief_title>
	<detailed_description>This study `` N one '' trial patient control . We provide quality life questionnaire , MOS-HIV questionnaire ; ISR questionnaire satisfaction questionnaire patient use standard need inject enfuvirtide least one month . As well , demographic laboratory data collect . The procedure give 1 month use Biojector follow-up visit .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>Patients take enfuvirtide least one month Patients hemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Injection site reaction</keyword>
	<keyword>enfuvirtide administration</keyword>
</DOC>